Prakiraan wutah bathi kanggo taun ngarep karunatx.com (KRTX)

Shifting analyst expectations for EPS growth in the next fiscal year demonstrate the potential of Karuna Therapeutics (KRTX), underpinned by massive investments in the development of a schizophrenia drug and a future high-margin monopoly. Meanwhile, the implementation of ESG environmental standards requires the company to optimize its chemical cycles. The value of 51.10 captures the metric level, accounting for insurance coverage risks and high medical personnel expenses.
Rincian analitis lan laporan data perusahaan Karuna Therapeutics Inc (KRTX)

This indicator is calculated as the percentage ratio of expected net earnings per share to the current value, reflecting the market consensus on business scaling rates. For Karuna Therapeutics (KRTX), whose team successfully integrated an innovative drug into the structure of a pharma behemoth, the analyst EPS growth chart on GURU.Markets visualizes market confidence in the monetization of new assets and the potential for future capitalization.